<DOC>
	<DOCNO>NCT01695668</DOCNO>
	<brief_summary>The purpose research : 1 . Evaluate safety efficacy steroid eye drop ( Lotemax ) patient diagnose graft-versus-host disease ( GVHD ) , complication may occur bone marrow transplant newly transplant material attack patient 's body may cause eye dryness . 2 . Assess safety efficacy Lotemax decrease eye 's reaction process GVHD patient undergoes bone marrow transplant . 3 . Compare well Lotemax work decrease process GVHD immunosuppressive eye drop ( Restasis ) , commonly use treatment condition .</brief_summary>
	<brief_title>Treatment Ocular Graft-versus-Host Disease ( GVHD ) With Topical Loteprednol Etabonate 0.5 %</brief_title>
	<detailed_description>Allogeneic bone marrow peripheral stem cell transplantation result Graft-versus-Host disease . Ocular symptom may first presentation GVHD may see absence systemic manifestation . GVHD categorize acute chronic form define 100 day transplant . Acute GVHD characterize dermatitis , hepatitis , enteritis . Chronic GVHD involve skin , mouth , liver , gastrointestinal tract , lung , eye . Ocular GVHD common cause dry eye symptom patient undergo bone marrow transplant ( BMT ) , define ocular surface disease context GVHD . Dry eye develop 76 % acute GVHD patient 62.5 % 81.8 % chronic GVHD patient . Current treatment ocular GVHD include topical cyclosporine 0.05 % ( Restasis , Allergan ) . Topical loteprednol etabonate 0.5 % ( Lotemax , Bausch Lomb ) show safe efficacious treatment inflammatory ocular disorder , prospectively study ocular GVHD . 2 . Hypothesis : We anticipate topical loteprednol etabonate 0.5 % safe efficacious treatment ocular GVHD patient , would add armamentarium therapeutic disease . Further , follow natural progression disease prior patient 's Bone Marrow Transplant ( BMT ) , may elucidate new standard care patient - one involve referral ophthalmologist ocular GVHD symptom arise .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Scheduled allogenic bone marrow transplant Allergic reaction loteprednol cyclosporine , previous allogenic transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Graft versus Host Disease ( GVHD )</keyword>
	<keyword>dry eye</keyword>
	<keyword>Bone marrow transplant ( BMT )</keyword>
	<keyword>Restasis</keyword>
	<keyword>Lotemax</keyword>
</DOC>